Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 1.00 |
| ▸ | HTR2B | P41595 | 20/20 | 1.00 |
| ▸ | HTR2A | P28223 | 18/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | HTR6 | P50406 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8116621 | 0.92 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| SCHEMBL8132984 | 0.91 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| SCHEMBL8118145 | 0.90 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| SCHEMBL7543461 | 0.89 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| SCHEMBL7540136 | 0.86 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL7540345 | 0.86 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| Sb-243213 SCHEMBL31060820 | 0.84 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-243213 SCHEMBL29697170 | 0.84 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-243213 SCHEMBL677610 | 0.84 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-243213 SCHEMBL7473195 | 0.83 | HTR2C (0.98) | HTR2CHTR2BHTR2ACYP2C9HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003011281-A1 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER OR ATTENTION DEFICIT DISORDER | VERNALIS RESEARCH LIMITED (GB) | 2003-02-13 | — | — | WO | claimed |
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM P.L.C. | 2002-03-21 | — | — | US | claimed |
| US-6313145-B1 | FOR THERAPY OF ANXIETY AND/OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-06 | — | — | US | claimed |
| EP-0912556-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-04 | — | — | EP | claimed |
| US-8324246-B2 | Indol carboxylic acid bispyridyl carboxamide derivatives, pharmaceutically acceptable salt thereof, preparation method and composition containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-04 | — | — | US | disclosed |
| US-8324246-B2 | Indol carboxylic acid bispyridyl carboxamide derivatives, pharmaceutically acceptable salt thereof, preparation method and composition containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-04 | — | — | US | disclosed |
| US-20090258876-A1 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-10-15 | — | — | US | disclosed |
| US-20090258876-A1 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-10-15 | — | — | US | disclosed |
| WO-2009125923-A2 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-10-15 | — | — | WO | disclosed |
| EP-2108649-A1 | Novel indol carboxylic acid bispyridyl carboxamide derivatives as 5-HT2c receptor antagonists | Korea Research Institute of Chemical Technology (KR) | 2009-10-14 | — | — | EP | disclosed |
| EP-1251829-A4 | ELECTROSPUN PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BEECHAM CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2003011281-A1 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER OR ATTENTION DEFICIT DISORDER | VERNALIS RESEARCH LIMITED (GB) | 2003-02-13 | — | — | WO | disclosed |
| US-20030017208-A1 | Electrospun pharmaceutical compositions | SMITHKLINE BEECHAM CORPORATION | 2003-01-23 | — | — | US | disclosed |
| EP-1251829-A1 | ELECTROSPUN PHARMACEUTICAL COMPOSITIONS | SmithKline Beecham Corporation (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM P.L.C. | 2002-03-21 | — | — | US | disclosed |
| US-6313145-B1 | FOR THERAPY OF ANXIETY AND/OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-06 | — | — | US | disclosed |
| WO-2001054667-A1 | ELECTROSPUN PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-0912556-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-04 | — | — | EP | disclosed |
| EP-0912556-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048700-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258876-A1 | NOVEL INDOL CARBOXYLIC ACID BISPYRIDYL CARBOXAMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD AND COMPOSITION CONTAINING THE SAME AS AN ACTIVE INGREDIENT | HTR2C, HTR5A, HTR2A | HTR2C 1/4885HTR2B 8/4885HTR2A 3/4885 |
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | HTR2C, HTR1A, HTR1D | HTR2C 1/4885HTR2B 17/4885HTR2A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.